A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 456 participants.
Also called NCT07521007
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 456 participants
- Sponsor
- Registry
-
NCT07521007
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Australia, Canada, China
- Registry status
- Recruiting
Technical summary
Registry record NCT07521007. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-31 (actual); primary completion 2027-07-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
- Acronym
- PURIFY-TIMI 81
- Condition
- Atherosclerosis
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- YN001/Placebo 40mg
- Intervention (Drug)
- YN001/Placebo 20mg
- Intervention (Drug)
- YN001/Placebo 0mg
- Lead sponsor
- Beijing Inno Medicine Co., Ltd.
- Collaborator
- The TIMI Study Group
Record details
- Record id
cardio:ct-nct07521007- Content hash
42e390fed7cffcfc26ab98909037237ede5849180ee9008260994730aa195263